Publications by authors named "Marios Koumourtzis"
Background: Primary cutaneous B-cell lymphomas (PCBCLs) are rare cutaneous neoplasms with limited literature regarding treatment options and associated treatment outcomes. This study aimed to investigate and present real-world treatment outcomes in patients with PCBCLs.
Methods: All patients with PCBCL who were treated in five major referral centers for cutaneous lymphoma in Greece over 10 years were retrospectively included with their baseline characteristics and treatment-associated outcomes collected and analyzed.
Article Synopsis
- - The study analyzed the effectiveness and safety of methotrexate (MTX) in treating mycosis fungoides (MF) across different stages, involving 211 patients from five Greek centers, with a median age of 68.3 years.
- - Results showed an overall response rate of 55.5%, with better outcomes in patients receiving MTX as a first-line treatment and those with erythrodermic disease compared to tumor stage disease.
- - The study concludes that MTX is a viable first-line treatment option for MF, demonstrating varying progression-free survival rates depending on the disease stage and acceptable safety profiles.
Background: Psoriasis and psoriatic arthritis are chronic inflammatory skin and joint diseases requiring effective therapies. Although clinical studies have shown the efficacy of IL-23 inhibitors, real-world data are limited.
Methods: We conducted a single-center retrospective Greek study enrolling patients with psoriatic arthritis and moderate-to-severe plaque psoriasis being treated at our multidisciplinary psoriasis outpatient clinic.
Chlormethine is a bifunctional cytotoxic alkylating agent that binds to DNA, resulting in cell death (apoptosis). Chlormethine (also known as mechlorethamine) gel (CL gel) was approved in the European Union in 2017 and was first used in 2019. The aim of the study is to examine evidence regarding the efficacy and safety of chlormethine gel in everyday clinical experience from a cutaneous lymphoma centre.
View Article and Find Full Text PDFIntroduction: Chlormethine gel is a skin-directed therapy recommended for patients with early-stage mycosis fungoides (MF) cutaneous T cell lymphoma.
Methods: Herein, we present three cases of patients with stage IB-IIB MF who were treated with chlormethine gel and concomitant therapies.
Results: All patients responded well to treatment with chlormethine gel; complete responses were observed with improvements in Modified Severity-Weighted Assessment Tool scores and severity of lesions; one patient reported an improvement in quality of life.